A Phase 3 interventional study of alendronate in Paget's Disease of Bone, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-08-14.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To test the safety, effectiveness of MK0217 when taken once a week for six months in treating patients with Paget's bone disease.
21 studies on the registry are indexed under Osteitis Deformans; 1 is open to participants now.
This study's enrollment of 60 is above the median of 52 across 13 interventional studies indexed under Osteitis Deformans.
Browse Osteitis Deformans studies →Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Duration of Treatment : 6 Months
Also known as: MK0217
Patients will have a decrease of at least 30% in their blood alkaline phosphatase level after 6 months
MK0217 will be safely tolerated
No study locations are listed for this record.
The record gives a start of Oct 2001, a primary completion of Oct 2002 and a completion of Oct 2002. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alendronate